series-b
Stage
1
Investors
About
Sagitta Biotech develops active virosome technology based on a highly modified, non-replicating measles virus to produce vaccines, targeted cancer immunotherapies, and gene therapies by delivering up to six foreign genes on self-replicating RNA.
Explore Sagitta Biotech's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.